Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity-the early RA network (ERAN)

Rheumatology

Volumn 50, Issue 5, 2011, Pages 926-931

  Kiely, Patrick ^a   Walsh, David ^b   Williams, Richard ^c   Young, Adam ^d  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b SHERWOOD FOREST HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c WYE VALLEY NHS TRUST   (United Kingdom)

^d St Albans City Hospital   (United Kingdom)

Author keywords

28 Joint disease activity score; DMARD; Early rheumatoid arthritis; HAQ

Indexed keywords

ANALGESIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; STANDARDIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DISABILITY EVALUATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955156664     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq406     Document Type: Article

References (18)

1. NICE. Rheumatoid arthritis: the management of rheumatoid arthritis in adults. National Institute of Health and Clinical Excellence. http://www.nice.org.uk/Guidance/CG79 (February 2009, date last accessed).
2. Kiely PDW, Brown AK, Edwards CJ et al. Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. Rheumatology 2009;48:765-72.
3. Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
4. Schoels M, Knevel R, Aletaha D et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010;69:638-43.
5. NICE TA 130. http://www.nice.org.uk/nicemedia/live/11867/37914/37914.pdf (September 2010, date last accessed).
6. Irish guidelines. http://www.isr.ie/_fileupload/File/ISR%20Guidelines%20A4%20(3).pdf (2010, date last accessed).
7. Fautrel B, Pham T, Mouterde G et al. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine 2007;74:627-37.
8. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59: 762-84.
9. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
10. Deighton C, Hyrich K, Ding T et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology 2010;49:1197-9.
11. Dixey J, Jayakumar K, Koduri G et al. Disease activity and five year outcome of early rheumatoid arthritis in a biologic drug free cohort. Rheumatology 2009;48(Suppl. 1):i136.
12. Hyrich KL, Deighton C, Watson KD. BSRBR Control Centre Consortium, Symmons DPM, Lunt M. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology 2009;48: 1323-7.
13. Kiely PDW, Williams R, Walsh D, Young A. for the Early Rheumatoid Arthritis Network (ERAN). Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis; the ERAN cohort. Rheumatology 2009;48:57-60.
14. Van Vollenhoven RF, Ernestam S, Geborek P et al. Addition of infliximab compared with addition of sulphasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (SWEFOT trial): 1-year results of a randomised trial. Lancet 2009;374: 459-66.
15. Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
16. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early Outcome in moderate RA and non-biologic therapy in ERAN rheumatoid arthritis (the BeSt study). Arthritis Rheum 2005;52:3381-90.
17. Verschueren P, Esselens G, Westhovens R. Daily practice effectiveness of a step-down treatment in comparison with a tight a step-up for early rheumatoid arthritis. Rheumatology 2008;47:59-64.
18. Fransen J, Bernelot Moens H, Speyer I, van Riel PLCM. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005; 64:1294-8.